E. Ohman J or Asset Management AB Takes $2.04 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• E. Ohman J or Asset Management AB acquired a new stake in Edwards Lifesciences Corporation, purchasing 26,055 shares valued at approximately $2.04 million.
• Several institutional investors, including Jennison Associates LLC and UBS AM, have increased their holdings in Edwards Lifesciences, reflecting strong investor interest with 79.46% of the company's stock owned by institutional investors.
• Analysts have raised their price targets for Edwards Lifesciences, with a consensus target price now at $86.26 and ratings ranging from Strong Buy to Hold.

E. Ohman J or Asset Management AB acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,055 shares of the medical research company's stock, valued at approximately $2,038,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after acquiring an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Edwards Lifesciences by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock valued at $491,673,000 after acquiring an additional 264,311 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Edwards Lifesciences by 8.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after acquiring an additional 513,468 shares in the last quarter. Nuveen LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $330,881,000. Finally, Invesco Ltd. increased its holdings in shares of Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock valued at $310,773,000 after acquiring an additional 107,241 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on EW shares. Evercore ISI upped their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Mizuho upped their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Barclays upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.26.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Down 1.9%

Shares of NYSE:EW opened at $76.10 on Tuesday. The company has a market capitalization of $44.68 billion, a PE ratio of 10.95, a price-to-earnings-growth ratio of 3.74 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a fifty day moving average price of $78.91 and a two-hundred day moving average price of $75.48. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.